Epidemiology of adverse drug reactions in the elderly by drug class

Drugs and Aging

Volumn 14, Issue 3, 1999, Pages 231-239

  Beyth, Rebecca J ^a,c   Shorr, Roll I ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; INSULIN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONYLUREA; WARFARIN;

ADVERSE DRUG REACTION; AGE; AGED; AGING; ARTHRITIS; BLEEDING; CANCER; CHRONIC DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG SAFETY; ERYTHEMA; GASTROINTESTINAL HEMORRHAGE; GERIATRIC CARE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; PATHOLOGY; PATIENT COMPLIANCE; PEPTIC ULCER; PHARMACODYNAMICS; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STROKE; UREMIA;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0032974023     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914030-00005     Document Type: Review

References (76)

1. Ostrom JF, Hammarlund ER, Christensen DB, et al. Medication usage in an elderly population. Med Care 1985; 23: 157-64
2. US Department of Health and Human Services. Healthy people 2000: National health promotion and disease prevention objectives. Washington, DC: Government Printing Office, 1991
3. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995; 155: 1949-56
4. Classen DC, Pestotnik SL, Evans S, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997, 277: 301-6
5. Kannry JL, Chalmers TC, Orca M, et al. Neglect of aged in clinical trials [abstract]. Controlled Clin Trials 1989; 348
6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 263: 3255-64
7. Collet JP, Boivin JF, Spitzer WO, et al. Bias and confounding in pharmacoepidemiology. New York: John Wiley and Sons, 1994: 609-27
8. Avorn J, Gurwitz J. Principles in pharmacology. In: Cassel CK, Reisenberg DE, Sorensen LB, et al. Geriatric medicine. New York: Springer-Verlag, 1990: 68-77
9. Gurwitz JH, Gore JM, Goldberg RJ, et al. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 1996; 124: 283-91
10. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11
11. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-55
12. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12
13. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989; 1: 175-9
14. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Stroke prevention in atrial fibrillation study: final result. Circulation 1991; 84: 527-39
15. McCrory DC, Matchar DB, Samsa G, et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation. Arch Intern Med 1995; 155: 277-81
16. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151: 1950-3
17. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-73
18. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996; 11: 713-20
19. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996; 11: 721-8
20. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956-66
21. Bergman HD, Aoki VS, Black HJ, et al. A new role for the pharmacist in the detection and evaluation of adverse drug reactions. Am J Hosp Pharm 1971; 28: 343-50
22. Hurwitz N. Predisposing factors in adverse reactions to drugs. BMJ 1969; 1: 536-9
23. Klein U, Klein M, Sturm H, et al. The frequency of adverse drug reactions as dependent upon age, sex, and duration of hospitalization. Int J Clin Pharmacol Biopharm 1976; 13: 187-95
24. Levy M, Kletter-Hemo D, Nir I, et al. Drug utilization and adverse drug reactions in medical patients: comparison of two periods. Isr J Med Sci 1977; 13: 1065-71
25. Olgilvie RI, Ruedy J. Adverse drug reactions during hospitalization. Can Med Assoc J 1967; 97: 1450-7
26. Seidl LG, Thornton GF, Smith JW, et al. Studies on the epidemiology of adverse drug reactions; III. reactions in patients on a general medical service. Bull John Hopkins Hosp 1966; 119: 299-315
27. Smidt NA, McQueen EG. Adverse reactions to drugs: a comprehensive hospital inpatient survey. N Z Med J 1972; 76: 397-401
28. Hutchinson TA, Flegel KM, Kramer MS, et al. Frequency, severity and risk factors for adverse drug reactions in adult outpatients: a prospective study. J Chronic Dis 1986; 39: 533-42
29. Kellaway GS, McCrae E. Intensive monitoring for adverse drug effects in patients discharged from acute medical wards. N Z Med J 1973; 78: 525-8
30. Smith JW, Seidl LG, Cluff LE. Studies on the epidemiology of adverse drug reactions; V. clinical factors influencing susceptibility. Ann Intern Med 1966; 65: 629-40
31. Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: a multicenter investigation. Age Ageing 1980; 9: 73-80
32. Grymonpre RE, Mitenko PA, Sitar DS, et al. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988; 36: 1092-8
33. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: 901-4
34. Nolan L, O'Malley K. Prescribing for the elderly: part II. prescribing patterns: difference due to age. J Am Geriatr Soc 1988; 36: 245-54
35. Guralnik JM, LaCroix AZ, Everett DF, et al. Aging in the eighties: the prevalence of comorbidity and association with disability. In: Anonymous. Advance data from vital and health statistics, no. 170. Hyattsville (MD): National Center for Health Statistics, 1989
36. Seeman TE, Guralnik J, Kaplan GA, et al. The health consequences of multiple morbidity in the elderly: the Alameda County study. J Aging Health 1989; 1: 50-66
37. US Senate Special Committee on Aging (1987-88). Aging America, 1988: trends and projections. Washington, DC: US Department of Health and Human Services, 1991
38. Toohey M. Clinical trial of phenylindanedione as an anticoagulant. BMJ 1953; 1: 650-62
39. O'Malley K, Stevenson IH, Ward CA, et al. Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol 1977; 4: 309-14
40. Shepherd AMM, Hewick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4: 315-20
41. Friedman SA. Organ systems: cardiovascular disorders. In: Abrams WB, Berkow R (editors). The merck manual of geriatrics. Rahway (NJ): Merck Sharp and Dohme Research Laboratories, 1990: 408
42. Masuda J, Tanak K, Ueda K, et al. Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan. Stroke 1988; 19: 205-10
43. Vonsattel JP, Myers RH, Hedley-Whyte ET, et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991; 30: 637-49
44. Hylek EM, Singer DE. Risk factor for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902
45. Beyth RJ, Landefeld CS. Anticoagulants in older patients: a safety perspective. Drugs and Aging 1995; 6: 45-54
46. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 687-91
47. Fihn SD, Callahan CM, Martin DC, et al. The risk and severity of bleeding complications in elderly patients treated with warlarin. Ann Intern Med 1996; 124: 970-9
48. Beyth RJ, Landeteld CS. Are older patients at increased risk for major bleeding during anticoagulant therapy? [abstract]. Clin Res 1992; 40: 552A
49. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118: 511-20
50. Gurwitz JH, Goldberg RJ, Holden A, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Arch Intern Med 1988; 148: 1733-6
51. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes 1997; 46: 271-86
52. Gold AE, Frier BM, MacLeod KM, et al. A structural equation model for predictors of severe hypoglycemia in patients with insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 309-15
53. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab 1994; 79: 1659-62
54. Harris MI. Epidemiology of diabetes mellitus among the elderly in the United States. Clin Geriatr Med 1990; 6: 703-19
55. Leibson CL, O'Brien PC, Atkinson E, et al. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study. Am J Epidemiol 1997; 146: 12-22
56. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: National Diabetes Data Group (editors). Diabetes in America. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Discases (NIDDK). National Institutes of Health; 1995, 47-68. Publication no. NIDDK-NIH-95-1468
57. Cowie CC, Port FK, Wolfe RA, et al. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321: 1074-9
58. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97
59. American Diabetes Association. Standards of medical care for patients with diabetes. Diabetes Care 1997; 20: S5-13
60. Turner R, Cull C, Holman R. United Kingdom prospective diabetes study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-45
61. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751-5
62. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681-6
63. Shorr RI, Ray WA, Daugherty JR, et al. Antihypertensives and the risk of serious hypoclycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40-3
64. Ruth SH. Salicytales revisited: are they still the hallmark of anti-inflammatory therapy? Drugs 1988; 36: 1-6
65. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Nonsteroidal anti-inflammatory drug-associated azotemia in the very old. JAMA 1990; 264: 471-5
66. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: we started it - can we stop it? Arch Intern. Med 1986; 146: 1075-6
67. Roth SH, Bennett RE, Mitchell CS, et al. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy: double-blind long-term evaluation. Arch Intern Med 1987; 147: 1798-801
68. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987; 28: 527-32
69. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647-66.
70. Collier DS, Pain JA. Nonsteroidal anti-inflammatory drugs and peptic ulcer perforation. Gut 1985; 26: 359-63.
71. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drag use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359-63
72. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-96
73. Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan Canada. J Clin Epidemiol 1988; 41: 35-45
74. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63
75. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
76. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior-authorization requirement on the use nonsteroidal anti-inflammatory drugs by Medicaid patients. N Engl J Med 1995; 332: 1612-7